Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD 2–4)
Roland Buhl(University of Applied Sciences Mainz), Eric Bateman(University of Cape Town), Lorcan McGarvey(Queen's University Belfast), Stella Waitere-Wijker(Boehringer Ingelheim (Netherlands)), Emílio Pizzichini(Universidade Federal de Santa Catarina), Lawrence Korducki(Boehringer Ingelheim (United States)), Matjaž Fležar(University Clinic of Pulmonary and Allergic Diseases Golnik), Leif Bjermer(Lund University), Eric Derom(Ghent University Hospital), Gary T. Ferguson(Pulmonary Associates), Antony Veale(Queen Elizabeth Hospital), François Maltais(Institut universitaire de cardiologie et de pneumologie de Québec), Henrik Watz(German Center for Lung Research), Kay Tetzlaff(Boehringer Ingelheim (Taiwan)), Jacques Hébert(Centre for Research in Astrophysics of Québec), Alan Hamilton(Boehringer Ingelheim (Canada)), Lars Grönke(Boehringer Ingelheim (Germany)), Jim Reid(University of Otago), R Abrahams(Pulmonary Associates)
Cited by 322
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation
|American Journal of Respiratory and Critical Care Medicine|2013|3.8k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
|New England Journal of Medicine|2014|621